Clinical trialNCT01549886TerminatedPhase 2Interventional

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

SponsorSpectrum Pharmaceuticals, IncEnrollment5Non-Hodgkin's Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The objectives of this study are to evaluate the efficacy and safety of the Zevalin regimen compared to Zevalin and motexafin gadolinium in patients with rituximab-refractory, low-grade or follicular Non-Hodgkin's Lymphoma (NHL). Effectiveness of the experimental regimen assessed by complete response rate within 6 months of study entry (primary endpoint), complete response rate within 3 months of study entry, and overall response rate within 6 month of study entry.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Andrew M Evens, DO, MSc
University of Massachusetts, Worcester
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Alta Bates Summit Medical Center-Herrick
Berkeley, California, United States
Providence Saint Joseph Medical Center
Burbank, California, United States
Halifax Health- Center for Oncology
Daytona Beach, Florida, United States
Rush University Medical Center
Chicago, Illinois, United States
Loyola University Chicago
Maywood, Illinois, United States
Oncology Specialists
Park Ridge, Illinois, United States
University of Massachusetts - Worcester
Worcester, Massachusetts, United States
Hackensack Medical Center
Hackensack, New Jersey, United States
West Virginia University, Wvu Healthcare
Morgantown, West Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Moxtezafin GadoliniumRituximab →Y-90-Zevalin

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Nov 2011
Primary completion: 30 Jun 2014
Completion: 31 May 2015
Last update posted: 4 Oct 2021
Registered enrollment: 5
Registry id: NCT01549886

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.